BioCardia Past Earnings Performance
Past criteria checks 0/6
BioCardia has been growing earnings at an average annual rate of 5%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 15% per year.
Key information
5.0%
Earnings growth rate
40.4%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 15.0% |
Return on equity | n/a |
Net Margin | -2,425.8% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns
Oct 12BioCardia stock rises on contract for delivery products for BlueRock's cell therapies
Aug 24Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?
Aug 24Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation
May 10We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully
Jan 06We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully
Sep 23Why I've Taken A Small Position In BioCardia
Jun 14Shareholders May Not Be So Generous With BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation And Here's Why
Jun 08Is BioCardia (NASDAQ:BCDA) In A Good Position To Deliver On Growth Plans?
May 20BioCardia issued U.S. patent for Helix Biotherapeutic Delivery system
Dec 30BioCardia slips 11% on launch of direct offering
Dec 16BioCardia says DSMB feedback on cell therapy data in heart failure study anticipated soon
Dec 14Revenue & Expenses BreakdownBeta
How BioCardia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -12 | 4 | 0 |
30 Sep 23 | 1 | -13 | 4 | 0 |
30 Jun 23 | 0 | -13 | 4 | 0 |
31 Mar 23 | 1 | -12 | 4 | 0 |
31 Dec 22 | 1 | -12 | 4 | 0 |
30 Sep 22 | 1 | -12 | 5 | 0 |
30 Jun 22 | 2 | -12 | 5 | 0 |
31 Mar 22 | 1 | -13 | 5 | 0 |
31 Dec 21 | 1 | -13 | 5 | 0 |
30 Sep 21 | 1 | -12 | 5 | 0 |
30 Jun 21 | 0 | -13 | 5 | 0 |
31 Mar 21 | 0 | -13 | 5 | 0 |
31 Dec 20 | 0 | -15 | 6 | 0 |
30 Sep 20 | 0 | -16 | 6 | 0 |
30 Jun 20 | 0 | -15 | 6 | 0 |
31 Mar 20 | 1 | -16 | 6 | 0 |
31 Dec 19 | 1 | -15 | 6 | 0 |
30 Sep 19 | 1 | -15 | 6 | 0 |
30 Jun 19 | 0 | -15 | 6 | 0 |
31 Mar 19 | 1 | -14 | 6 | 0 |
31 Dec 18 | 1 | -14 | 6 | 0 |
30 Sep 18 | 1 | -14 | 6 | 0 |
30 Jun 18 | 1 | -13 | 6 | 0 |
31 Mar 18 | 1 | -13 | 6 | 0 |
31 Dec 17 | 0 | -12 | 6 | 0 |
30 Sep 17 | 1 | -12 | 6 | 0 |
30 Jun 17 | 1 | -13 | 6 | 0 |
31 Mar 17 | 1 | -12 | 5 | 0 |
31 Dec 16 | 1 | -10 | 4 | 0 |
30 Sep 16 | 1 | -7 | 3 | 0 |
30 Jun 16 | 1 | -7 | 3 | 0 |
31 Mar 16 | 1 | -6 | 3 | 0 |
31 Dec 15 | 1 | -7 | 4 | 0 |
31 Mar 15 | 1 | -10 | 5 | 0 |
31 Dec 14 | 1 | -10 | 4 | 0 |
31 Dec 13 | 2 | -6 | 3 | 0 |
Quality Earnings: BCDA is currently unprofitable.
Growing Profit Margin: BCDA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BCDA is unprofitable, but has reduced losses over the past 5 years at a rate of 5% per year.
Accelerating Growth: Unable to compare BCDA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BCDA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: BCDA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.